Current status of multiple sclerosis therapy in Germany: a national survey

We conducted a semi-standardized enquiry concerning diagnostic, immunotherapeutic and supportive care strategies for multiple sclerosis (MS). A questionnaire was sent to all German neurological departments in December 1996, with 63% (n = 244) responding before May 1997. As might be expected, MS therapy in Germany is not very standardized. Most clinics use intravenous steroids for treating relapses, although with different dosing regimens. Nevertheless, oral steroids are also used. Interferon-beta and azathioprine are both used for the treatment of relapsing-remitting MS at the same frequency. Only 33% of German neurological departments said that they used an immunomodulating agent for chronic-progressive cases, indicating it in about 50% of cases. Azathioprine is the drug of first choice, followed by methotrexate. Regarding supportive care measures, the technique of intermittent self-catheterization is widely under-represented. Despite the lack of conclusive evidence from prospective studies for the value of azathioprine, it is still one of the most commonly used drugs for the treatment of relapsing-remitting and chronic-progressive MS. There was no evidence of a consensus on treatment standards for chronic-progressive disease courses.     

Über ein intramedulläres cavernöses Angiom

Zusammenfassung Bei einer 42jährigen Patientin konnte ein äußerst seltenes, intramedulläres cavernöses Angiom operativ entfernt werden. Sie war 7 Jahre erfolglos unter der Diagnose einer Multiplen Sklerose behandelt worden. Die Schwester der Patientin war vorher wegen einer angiomatösen Gefäßanomalie im Großhirn operiert worden.

---

Summary An extremely rare intramedullary cavernous angioma was operatively removed from a 42 year old female patient. She had been unsuccessfully treated for seven years with a diagnosis of multiple sclerosis. The patient's sister had previously been operated upon for an angiomatous malformation of the brain.

---

Resumen En una enferma de 42 años se extirpó un angioma cavernoso intramedular de una extrema rareza. Habia sido tratada durante 7 años, sin resultado, bajo el diagnóstico de esclerosis múltiple. La hermana de la enferma fué operada preventivamente de una malformación angiomatosa cerebral.

---

Résumé Un angiome caverneux intramédullaire extrêmement rare a eté enlevé chez une malade de 42 ans. Elle avait été traitée sans résultats pendant 7 ans avec le diagnostic de sclérose multiple. La soeur de la malade fut opérée préventivement d'une malformation angiomateuse cérébrale.

---

Riassunto Una paziente di 42 anni è stata operata radicalmente di un raro angioma cavernoso endomidollare. Essa è stata curata per 7 anni con la diagnosi di sclerosi multipla. La sorella delia paziente era già stata operata di una malformazione vascolare congenita del cervello.

     

Treatment of Patients with Early Breast Cancer: Evidence,Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference

This yearʼs 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title “Customizing local and systemic therapies for women with early breast cancer” focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie e. V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient.Key words: St. Gallen Consensus 2021, early breast cancer, surgery, radiotherapy, (neo)adjuvant systemic therapy, targeted therapy     

über einen Fall von Eifersuchtswahn bei Morbus Parkinson

Eifersuchtswahn kommt bei unterschiedlichen organischen und “funktionellen” psychotischen St?rungen vor. Bei organischen Psychosen bestehen zumeist über den Wahn hinaus Orientierungsst?rungen oder andere kognitive Symptome. Zur Assoziation mit Morbus Parkinson gibt es bislang kaum Fallberichte. In der vorliegenden Arbeit wird der Fall eines 49-j?hrigen Parkinsonpatienten mit Eifersuchtswahn hinsichtlich des klinischen Bildes sowie der Therapie und des Verlaufs vorgestellt und mit Bezug auf m?gliche neurobiologische Korrelate wahnhafter St?rungen diskutiert.     

Methotrexate in therapy of gastrointestinal diseases]

This review is not only a comprehensive synopsis of the published data on methotrexate treatment for inflammatory bowel disease and primary biliary cirrhosis but gives also an overview about acting mechanisms, pharmacologic properties and limiting toxicities of low-dose methotrexate. Methotrexate and its polyglutamate analogues are structurally related to folic acid and inhibit many enzymes in the metabolic pathway of folic acid. Long-term low-dose methotrexate treatment (7.5-25 mg) inhibits production of thymidylate, purines, and methionine and leads to intracellulary accumulation of adenosin. These actions lead to inhibition of cellular proliferation, decreased formation of antibodies and reduced productions of inflammatory medicators. Several trials have demonstrated the efficacy of low-dose methotrexate therapy for certain indications as a promising new agent in the treatment of inflammatory bowel disease and primary biliary cirrhosis. However, several serious toxicities potentially limit its use.     

Progressive renal failure in spontaneous-onset cholesterol crystal embolism

CASE REPORT: A 69-year-old man was admitted to the authors' hospital with an increase of plasma creatinine from 1.4 up to 4.9 mg/dl within 4 months and the clinical complaints of painful purple toes, recurrent epistaxis and disturbances of equilibrium. His past medical history was remarkable for three transient ischemic attacks and the diagnosis of a metabolic syndrome. Magnetic resonance imaging showed vasculitis-like lesions in the brain. Eosinophilia and tubular proteinuria were detected. Renal insufficiency was caused by cholesterol crystal embolism, as shown both by skin and renal biopsy. Aortic plaques were identified as the putative source of cholesterol embolization. CONCLUSION: In case of rapidly progressive renal failure, cholesterol crystal embolism must be considered even without preceding angiography.     

Risk factors for well-differentiated thyroid carcinoma in patients with thyroid nodular disease.

OBJECTIVES: Evaluate current accepted risk factors for well-differentiated thyroid carcinoma, and develop a predictive model to determine one's risk of malignancy given a thyroid nodule. STUDY DESIGN: Retrospective analysis of 600 patients. SUBJECTS AND METHODS: Patients with benign thyroid nodular disease and with well-differentiated thyroid cancer were randomly selected. Patient, clinical, and investigational data were compared by means of univariate and multivariate regression analyses. RESULTS: Age, regional lymphadenopathy, ipsilateral vocal cord palsy, solid and/or calcified nodules, and an aspiration biopsy being malignant or suspicious predicted for cancer (P < 0.05). Regional lymphadenopathy and vocal cord palsy are perfect predictors of malignancy. Multivariate analysis indicated age, solid and/or calcified nodules, and all fine-needle aspiration biopsy results to be significant in assessing risk (P < 0.05). CONCLUSION: Taking individual risk factors in isolation is not always reliable. Using a predictive model, one can anticipate a patient's risk of malignancy when the diagnosis is unclear.     

The prevalence of allergic diseases in an unselected group of 6-year-old children. The DARC birth cohort study

This study determines the prevalence of atopic dermatitis, asthma, rhinoconjunctivitis, food hypersensitivity and urticaria and the frequency of sensitization in children with and without clinical allergic disease. In an ongoing prospective non-interventional birth cohort study of 562 unselected children, 404 children were subjected to interview, clinical examination, lung function measurements and allergy testing at 6 yr of age. Sensitization measured by skin prick test (SPT) and specific immunoglobulin E (S-IgE) was determined for 24 different allergens. The 1-yr period prevalence of atopic dermatitis, asthma and rhinoconjunctivitis was 14.4%, 6.2% and 13.6%. 25.7% of the children suffered from at least one of the three diseases. The frequency of sensitization in children with no disease (controls), any allergic disease, atopic dermatitis, asthma and rhinoconjunctivitis was 17%, 45%, 47%, 56% and 55% (defined as SPT ≥3 mm and/or S-IgE ≥0.35 kU/l for at least one allergen). Symptoms were linked to sensitization for 44% in the asthma group and 42% in the rhinoconjunctivitis group, whereas sensitization could not be linked to worsening of the eczema in any cases of atopic dermatitis. Overlap between the three diseases was significantly more frequent in sensitized children than in non-sensitized (19/46 = 41% vs. 9/58 = 16%, p = 0.004). The prevalence of food hypersensitivity and urticaria was 1.2% and 5.4% respectively. In unselected 6 yr old children, approximately half of the children with atopic dermatitis, asthma or rhinoconjunctivitis are IgE-sensitized. Sensitization tends to link these diseases to each other.